Cangene is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. Four of our hyperimmune products have been approved in the United States and/or Canada, and three products are included in the U.S. Strategic National Stockpile.

With the commercial introduction of our first drug, WinRho® SDF, in 1980, we have established a lengthy history and a solid track record. We have been listed on the Toronto Stock Exchange since 1991 under the symbol CNJ.